Cited by 105Viral Infections and Immunology Researchinterferon and immune responsesMosquito-borne diseases and control

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Fluoxetine Is a Potent Inhibitor of Coxsackievirus Replication

Open access

Zuo, Jun, Quinn, Kevin K., Kye, Steve, Cooper, Paige, Damoiseaux, Robert, Krogstad, Paul·2012·Antimicrobial Agents and Chemotherapy

DOI 10.1128/aac.00983-12PMC PMC3421851

Open this paper in CoChat — free account

Abstract

No antiviral drugs currently exist for the treatment of enterovirus infections, which are often severe and potentially life threatening. Molecular screening of small molecule libraries identified fluoxetine, a selective serotonin reuptake inhibitor, as a potent inhibitor of coxsackievirus replication. Fluoxetine did not interfere with either viral entry or translation of the viral genome. Instead, fluoxetine and its metabolite norfluoxetine markedly reduced the synthesis of viral RNA and protein. In view of its favorable pharmacokinetics and safety profile, fluoxetine warrants additional study as a potential antiviral agent for enterovirus infections.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1128/aac.00983-12

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Enterovirus Surveillance - United States, 1970-2005: (540562006-001)
Khetsuriani, N., LaMonte-Fowlkes, A., Oberste, M. S., & Pallansch, M. A. (2006) · PsycEXTRA Dataset · doi:10.1037/e540562006-001 · Cited by 702
Molecular Epidemiology and Evolution of Enterovirus 71 Strains Isolated from 1970 to 1998
Brown, B. A., Oberste, M. S., Alexander, J. P., Kennett, M., & Pallansch, M. A. (1999) · Journal of Virology · doi:10.1128/jvi.73.12.9969-9975.1999 · Cited by 431
Use of Selective Serotonin Reuptake Inhibitors and Risk of Upper Gastrointestinal Tract Bleeding: A Population-Based Cohort Study
Dalton, S. O., Johansen, C., Mellemkjær, L., Sørensen, H. T., Nørgård, B., & Olsen, J. H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.1.59 · Cited by 389
Treatment of Potentially Life-Threatening Enterovirus Infections with Pleconaril
Rotbart, H. A., Webster, A., & for the Pleconaril Treatment Registry Group (2001) · Clinical Infectious Diseases · doi:10.1086/318452 · Cited by 373
Textbook of Pediatric Infectious Diseases,
Hanshaw, J. B. (1981) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1981.02130350074027 · Cited by 278
Molecular Epidemiology of Human Enterovirus 71 Strains and Recent Outbreaks in the Asia-Pacific Region: Comparative Analysis of the VP1 and VP4 Genes
Cardosa, M. J., Perera, D., Brown, B. A., Cheon, D., Chan, H. M., Chan, K. P., Cho, H., & McMinn, P. C. (2003) · Emerging infectious diseases · doi:10.3201/eid0904.020395 · Cited by 272
A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3
Knowlton, K. U., Jeon, E., Berkley, N., Wessely, R., & Huber, S. A. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.7811-7818.1996 · Cited by 261
Evidence for Frequent Recombination within SpeciesHuman Enterovirus BBased on Complete Genomic Sequences of All Thirty-Seven Serotypes
Oberste, M. S., Maher, K., & Pallansch, M. A. (2003) · Journal of Virology · doi:10.1128/jvi.78.2.855-867.2004 · Cited by 258
Selective inhibitors of picornavirus replication
Palma, A. M. D., Vliegen, I., Clercq, E. D., & Neyts, J. H. (2008) · Medicinal Research Reviews · doi:10.1002/med.20125 · Cited by 258

Flagged first, then by citations

Show all 49 references

1 of the 49 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

FryEE StuartDI. 2010. Virion structure, p 59–72. In EhrenfeldDE RoosRP (ed), The picornaviruses. ASM Press, Washington, DC.
KhetsurianiN Lamonte-FowlkesA OberstS PallanschMA. 2006. Enterovirus surveillance—United States, 1970–2005. MMWR Surveill. Summ. 55:1–20.

Sorted by citations

The life cycle of non-polio enteroviruses and how to target it
Baggen, J., Thibaut, H. J., Strating, J. R. P. M., & van Kuppeveld, F. J. M. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0005-4 · Cited by 500
Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
Sukhatme, V. P., Reiersen, A. M., Vayttaden, S. J., & Sukhatme, V. V. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.652688 · Cited by 193
Human induced pluripotent stem cell–derived cardiomyocytes as an in vitro model for coxsackievirus B3–induced myocarditis and antiviral drug screening platform
Sharma, A., Marceau, C., Hamaguchi, R., Burridge, P. W., Rajarajan, K., Churko, J. M., Wu, H., Sallam, K. I., Matsa, E., Sturzu, A. C., et al. (2014) · Circulation Research · doi:10.1161/circresaha.115.303810 · Cited by 148
Enteroviruses in the early 21st century
Lugo, D. J., & Krogstad, P. A. (2015) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000303 · Cited by 144
Self-citation
Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus
Nekoua, M. P., Alidjinou, E. K., & Hober, D. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00688-1 · Cited by 143
Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants
Oskotsky, T., Marić, I., Tang, A., Oskotsky, B., Wong, R. J., Aghaeepour, N., Sirota, M., & Stevenson, D. K. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.33090 · Cited by 132
Recent progress in understanding coxsackievirus replication, dissemination, and pathogenesis
Sin, J., Mangale, V., Thienphrapa, W., Gottlieb, R. A., & Feuer, R. (2015) · Virology · doi:10.1016/j.virol.2015.06.006 · Cited by 111
Selective Serotonin Reuptake Inhibitor Fluoxetine Inhibits Replication of Human Enteroviruses B and D by Targeting Viral Protein 2C
Ulferts, R., van der Linden, L., Thibaut, H. J., Lanke, K. H. W., Leyssen, P., Coutard, B., Palma, A. M. D., Canard, B., Neyts, J. H., & van Kuppeveld, F. J. M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02084-12 · Cited by 105
Direct-acting antivirals and host-targeting strategies to combat enterovirus infections
Bauer, L., Lyoo, H., van der Schaar, H. M., Strating, J. R. P. M., & van Kuppeveld, F. J. M. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.03.009 · Cited by 97
Enteroviruses in X-Linked Agammaglobulinemia: Update on Epidemiology and Therapy
Bearden, D. R., Collett, M. S., Quan, P. L., Costa‐Carvalho, B. T., & Sullivan, K. E. (2016) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2015.12.015 · Cited by 91
Identification of Luteolin as Enterovirus 71 and Coxsackievirus A16 Inhibitors through Reporter Viruses and Cell Viability-Based Screening
Xu, L., Su, W., Jin, J., Chen, J., Li, X., Zhang, X., Sun, M., Sun, S., Fan, P., An, D., et al. (2014) · Viruses · doi:10.3390/v6072778 · Cited by 87
Enterovirus D68 Antivirals: Past, Present, and Future
Hu, Y., Musharrafieh, R. G., Zheng, M., & Wang, J. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00120 · Cited by 81
Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C
Ulferts, R., de Boer, S. M., van der Linden, L., Bauer, L., Lyoo, H., Maté, M. J., Lichière, J., Canard, B., Lelieveld, D., Omta, W. A., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02182-15 · Cited by 79
Fluoxetine Inhibits Enterovirus Replication by Targeting the Viral 2C Protein in a Stereospecific Manner
Bauer, L., Manganaro, R., Zonsics, B., Strating, J. R. P. M., Kazzi, P. E., Lopez, M. L., Ulferts, R., van Hoey, C., Maté, M. J., Langer, T., et al. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00179 · Cited by 79
Widely available lysosome targeting agents should be considered as potential therapy for COVID-19
Homolak, J., & Kodvanj, I. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106044 · Cited by 74
Enterovirus Persistence in Cardiac Cells of Patients With Idiopathic Dilated Cardiomyopathy Is Linked to 5’ Terminal Genomic RNA-Deleted Viral Populations With Viral-Encoded Proteinase Activities
Bouin, A., Gretteau, P.-A., Wehbe, M., Renois, F., N’Guyen, Y., Lévêque, N., Vu, M. N., Tracy, S., Chapman, N. M., Bruneval, P., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.035966 · Cited by 73
Acute Flaccid Paralysis and Enteroviral Infections
Bitnun, A., & Yeh, E. A. (2018) · Current Infectious Disease Reports · doi:10.1007/s11908-018-0641-x · Cited by 73
Rationale for the Evaluation of Fluoxetine in the Treatment of Enterovirus D68-Associated Acute Flaccid Myelitis
Tyler, K. L. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4625 · Cited by 67
Project IDentif.AI: Harnessing Artificial Intelligence to Rapidly Optimize Combination Therapy Development for Infectious Disease Intervention
Abdulla, A., Wang, B., Feng, Q., Kee, T. W., Blasiak, A., Ong, Y. H., Hooi, L., Parekh, F. K., Soriano, R., Olinger, G. G., et al. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000034 · Cited by 65
Synthesis and Structure–Activity Relationship (SAR) Studies of Novel Pyrazolopyridine Derivatives as Inhibitors of Enterovirus Replication
Xing, Y., Zuo, J., Krogstad, P. A., & Jung, M. E. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01863 · Cited by 65
Self-citation
Treatment of Chronic Enterovirus Encephalitis With Fluoxetine in a Patient With X-Linked Agammaglobulinemia
Gofshteyn, J. S., Cárdenas, A. M., & Bearden, D. R. (2016) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2016.06.014 · Cited by 59
Antimicrobial Properties of Antidepressants and Antipsychotics—Possibilities and Implications
Caldara, M., & Marmiroli, N. (2021) · Pharmaceuticals · doi:10.3390/ph14090915 · Cited by 54
Identification of dibucaine derivatives as novel potent enterovirus 2C helicase inhibitors: In vitro, in vivo, and combination therapy study
Tang, Q., Xu, Z., Jin, M., Shu, T., Chen, Y., Feng, L., Zhang, Q., Lan, K., Wu, S., & Zhou, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112310 · Cited by 48
Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?
Pashaei, Y. (2021) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2021.03.010 · Cited by 48
Is Autophagy Involved in the Diverse Effects of Antidepressants?
Rein, T. (2019) · Cells · doi:10.3390/cells8010044 · Cited by 45
Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort
Clelland, C. L. T., Ramiah, K., Steinberg, L. J., & Clelland, J. D. (2021) · BJPsych Open · doi:10.1192/bjo.2021.1053 · Cited by 45
Fluoxetine Can Inhibit SARS-CoV-2 In Vitro
Dechaumes, A., Nekoua, M. P., Belouzard, S., Sané, F., Engelmann, I., Dubuisson, J., Alidjinou, E. K., & Hober, D. (2021) · Microorganisms · doi:10.3390/microorganisms9020339 · Cited by 42
Fluoxetine targets an allosteric site in the enterovirus 2C AAA+ ATPase and stabilizes a ring-shaped hexameric complex
Hurdiss, D. L., Kazzi, P. E., Bauer, L., Papageorgiou, N., Ferrón, F., Donselaar, T., van Vliet, A. L. W., Shamorkina, T. M., Snijder, J., Canard, B., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj7615 · Cited by 41
Crystal structure of a soluble fragment of poliovirus 2CATPase
Guan, H., Tian, J., Zhang, C., Qin, B., & Cui, S. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007304 · Cited by 39
Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?
da Costa, L. H. A., Santos, B. M., & Branco, L. G. S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173629 · Cited by 40
Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: The possible role of the sigma-1 receptor and autophagy
Brimson, J. M., Prasanth, M. I., Malar, D. S., Brimson, S., Thitilertdecha, P., & Tencomnao, T. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1952987 · Cited by 36
Rational design of highly potent broad-spectrum enterovirus inhibitors targeting the nonstructural protein 2C
Bauer, L., Manganaro, R., Zonsics, B., Hurdiss, D. L., Zwaagstra, M., Donselaar, T., Welter, N. G. E., van Kleef, R. G. D. M., Lopez, M. L., Bevilacqua, F., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000904 · Cited by 37
N -Desmethylclozapine, Fluoxetine, and Salmeterol Inhibit Postentry Stages of the Dengue Virus Life Cycle
Medigeshi, G. R., Kumar, R., Dhamija, E., Agrawal, T., & Kar, M. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01367-16 · Cited by 35
Recent advances on the role of host factors during non-poliovirus enteroviral infections
Owino, C. O., & Chu, J. J. H. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0540-y · Cited by 34
Persistent infection of human pancreatic cells with Coxsackievirus B4 is cured by fluoxetine
Alidjinou, E. K., Sané, F., Bertin, A., Caloone, D., & Hober, D. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.01.010 · Cited by 34
Synthesis and antiviral effect of novel fluoxetine analogues as enterovirus 2C inhibitors
Manganaro, R., Zonsics, B., Bauer, L., Lopez, M. L., Donselaar, T., Zwaagstra, M., Saporito, F., Ferla, S., Strating, J. R. P. M., Coutard, B., et al. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104781 · Cited by 29
Structural Chemistry of Helicase Inhibition
Selvaratnam, L., Willson, T. M., & Schapira, M. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01909 · Cited by 28
Fluoxetine can inhibit coxsackievirus-B4 E2 in vitro and in vivo
Benkahla, M. A., Alidjinou, E. K., Sané, F., Desailloud, R., & Hober, D. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.10.002 · Cited by 27
Combating coxsackievirus B infections
Alhazmi, A., Nekoua, M. P., Mercier, A., Vergez, I., Sané, F., Alidjinou, E. K., & Hober, D. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2406 · Cited by 28
Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5
Loddo, R., Novelli, F., Sparatore, A., Tasso, B., Tonelli, M., Boido, V., Sparatore, F., Collu, G., Delogu, I., Giliberti, G., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.09.035 · Cited by 27
Fluoxetine a novel anti-hepatitis C virus agent via ROS-, JNK-, and PPARβ/γ-dependent pathways
Young, K.-C., Bai, C., Su, H., Tsai, P., Pu, C.-Y., Liao, C., Lin, Y., Lai, H.-W., Chong, L.-W., Tsai, Y.-S., et al. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.08.002 · Cited by 26
Discovery of Structurally Diverse Small-Molecule Compounds with Broad Antiviral Activity against Enteroviruses
Zuo, J., Kye, S., Quinn, K. K., Cooper, P., Damoiseaux, R. D., & Krogstad, P. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02646-15 · Cited by 24
Self-citation
Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day
Eugene, A. R. (2021) · F1000Research · doi:10.12688/f1000research.53275.1 · Cited by 22
Direct-Acting Antivirals and Host-Targeting Approaches against Enterovirus B Infections: Recent Advances
Tammaro, C., Guida, M., Appetecchia, F., Biava, M., Consalvi, S., & Poce, G. (2023) · Pharmaceuticals · doi:10.3390/ph16020203 · Cited by 21
Therapeutic targets for enterovirus infections
Laajala, M., Reshamwala, D., & Marjomäki, V. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1784141 · Cited by 19
Screening and identification of inhibitors against influenza A virus from a US drug collection of 1280 drugs
An, L., Liu, R., Tang, W. F., Wu, J., & Chen, X. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.06.007 · Cited by 19
Quantum tunnelling in the context of SARS-CoV-2 infection
Adams, B., Sinayskiy, I., van Grondelle, R., & Petruccione, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-21321-1 · Cited by 17
Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use
Foletto, V. S., da Rosa, T. F., Serafin, M. B., & Hörner, R. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03372-5 · Cited by 16
Compassionate-use pocapavir and immunoglobulin therapy for treatment of rituximab-associated enterovirus meningoencephalitis
Epstein, S., Thakkar, R., Fong, K. T., Ng, J., Bearden, D. R., Mishra, N., Thakur, K. T., & Riley, C. (2022) · Journal of NeuroVirology · doi:10.1007/s13365-021-01038-z · Cited by 15
Treatment of rituximab-associated chronic CNS enterovirus using IVIg and fluoxetine
Sham, L., Bitnun, A., Branson, H. M., Hazrati, L., Dell, S., Yeung, R. S. M., Johnstone, J., & Yeh, E. A. (2019) · Neurology · doi:10.1212/wnl.0000000000007468 · Cited by 14
Eradication of persistent coxsackievirus B infection from a pancreatic cell line with clinically used antiviral drugs
Honkimaa, A., Sioofy‐Khojine, A., Oikarinen, S., Bertin, A., Hober, D., & Hyöty, H. (2020) · Journal of Clinical Virology · doi:10.1016/j.jcv.2020.104334 · Cited by 14
The Current Recommended Drugs and Strategies for the Treatment of Coronavirus Disease (COVID-19)
Sheikhpour, M. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s262936 · Cited by 16
Structure Prediction and Potential Inhibitors Docking of Enterovirus 2C Proteins
Li, D., & Zhang, L. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.856574 · Cited by 10
Fighting Enteroviral Infections to Prevent Type 1 Diabetes
Nekoua, M. P., Mercier, A., Alhazmi, A., Sané, F., Alidjinou, E. K., & Hober, D. (2022) · Microorganisms · doi:10.3390/microorganisms10040768 · Cited by 9
An Overview of Fluvoxamine and its Use in SARS-CoV-2 Treatment
Arishi, N. A., Althomali, N., Dighriri, I. M., AlHarthi, M. S., Alqurashi, G. B., Musharraf, R. A., Albuhayri, A. H., Almalki, M. K., Alnami, S. A., & Mashraqi, Z. O. (2023) · Cureus · doi:10.7759/cureus.34158 · Cited by 10
Myocarditis, Disseminated Infection, and Early Viral Persistence Following Experimental Coxsackievirus B Infection of Cynomolgus Monkeys
Cammock, C. E., Halnon, N. J., Skoczylas, J., Blanchard, J., Bohm, R. P., Miller, C. J., Lai, C. K., & Krogstad, P. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074569 · Cited by 10
Self-citation
Acute Flaccid Myelitis: Characteristics and Outcomes of 2014 and 2016 Cases at a Single Center
Matesanz, S. E., McGuire, J. L., & Hopkins, S. E. (2019) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2019.07.015 · Cited by 10
Picornaviral 2C proteins: A unique ATPase family critical in virus replication
Chen, P., Li, Z., & Cui, S. (2021) · The Enzymes · doi:10.1016/bs.enz.2021.06.008 · Cited by 10
Automated cell-based luminescence assay for profiling antiviral compound activity against enteroviruses
Zhang, M., Zhang, Y., Wang, Y., Lv, W., & Zhang, Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-42160-7 · Cited by 9
Research progress and application prospects of animal models of group B Coxsackievirus infections
Weng, S., Zhu, R., Wu, Y., Xia, N., Xu, L., & Cheng, T. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2024.2441391 · Cited by 8
Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19
Anar, M. A., Foroughi, E., Sohrabi, E., Peiravi, S., Tavakoli, Y., Khouzani, M. K., Behshood, P., Shamshiri, M., Faridzadeh, A., Keylani, K., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1036093 · Cited by 11
Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day
Eugene, A. R. (2022) · F1000Research · doi:10.12688/f1000research.53275.2 · Cited by 7
Psychotropics and COVID-19: An analysis of safety and prophylaxis
Javelot, H., Straczek, C., Meyer, G., Faria, C. G. F., Weiner, L., Drapier, D., Fakra, É., Fossati, P., Weibel, S., Dizet, S., et al. (2021) · L Encéphale · doi:10.1016/j.encep.2021.08.002 · Cited by 6
Difficulty in Repurposing Selective Serotonin Reuptake Inhibitors and Other Antidepressants with Functional Inhibition of Acid Sphingomyelinase in COVID-19 Infection
Corre, P. L., & Loas, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.849095 · Cited by 6
Rubella virus chronic inflammatory disease and other unusual viral phenotypes in inborn errors of immunity
Kilich, G., Perelygina, L. M., & Sullivan, K. E. (2023) · Immunological Reviews · doi:10.1111/imr.13290 · Cited by 6
Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants
Thümmler, L., Beckmann, N., Sehl, C., Soddemann, M., Braß, P., Bormann, M., Brochhagen, L., Elsner, C., Hoertel, N., Cougoule, C., et al. (2024) · Viruses · doi:10.3390/v16040545 · Cited by 5
UCLA’s Molecular Screening Shared Resource: Enhancing Small Molecule Discovery with Functional Genomics and New Technology
Damoiseaux, R. D. (2014) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207317666140323134621 · Cited by 6
Self-citation
Emergence of Fluoxetine-Resistant Variants during Treatment of Human Pancreatic Cell Cultures Persistently Infected with Coxsackievirus B4
Alidjinou, E. K., Bertin, A., Sané, F., Caloone, D., Engelmann, I., & Hober, D. (2019) · Viruses · doi:10.3390/v11060486 · Cited by 6
Doxycycline inhibits neurotropic enterovirus proliferation in vitro
Chi, F., Liu, X., Li, J., Guo, M., Zhang, Z., Zhou, H., Carr, M. J., Li, Y., & Shi, W. (2024) · Virus Research · doi:10.1016/j.virusres.2024.199388 · Cited by 5
2C protein of Enterovirus: key protein of viral replication and antiviral target
Kazzi, P. E., Yaacoub, C., Fajloun, Z., Vanelle, P., Decroly, É., Coutard, B., & Barral, K. (2023) · Virologie · doi:10.1684/vir.2023.1002 · Cited by 5
Computational Drug Repositioning and Elucidation of Mechanism of Action of Compounds against SARS-CoV-2Preprint
Napolitano, F., Gambardella, G., Carrella, D., Gao, X., & Dd, B. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2004.07697 · Cited by 6
New fluoxetine analogues as anti-enterovirus agents targeting 2C protein
Khemiri, S., Faucher, M. O., Bourg, S., Attoumani-Madi, S., Yaacoub, C., Touret, F., Farag, M., Vitorino, M. F., Bonnet, P., Vanelle, P., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118621 · Cited by 4
Development of a fluorescence resonance energy transfer–based intracellular assay to identify novel enterovirus 71 antivirals
Lu, W.-W., Kung, F.-Y., Deng, P.-A., Lin, Y.-C., Lin, C., & Kung, S. (2016) · Archives of Virology · doi:10.1007/s00705-016-3143-x · Cited by 4
Natural Products as a Paradigm for the Treatment of Coxsackievirus - induced Myocarditis
Khanna, M., Gautam, A., Rajput, R., & Sharma, L. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200129094516 · Cited by 4
Novel Antiviral Activity of Ethyl 3-Hydroxyhexanoate Against Coxsackievirus B Infection
Olasunkanmi, O. I., Mageto, J., Ntsigouaye, J. A., Yi, M., Fei, Y., Chen, Y., Chen, S., Xu, W., Lin, L., Zhao, W., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.875485 · Cited by 4
Antiviral candidates for enterovirus 71: targeting viral proteome and stage-specific lifecycle interventions
Chen, J., Zhao, T. T.-Q., Ji, M., & Xia, B. (2025) · Virology Journal · doi:10.1186/s12985-025-02966-6 · Cited by 3
Herpes Simplex Virus-1 Induced Serotonin-Associated Metabolic Pathways Correlate With Severity of Virus- and Inflammation-Associated Ocular Disease
Battaglia, D. M., Sanchez‐Pino, M. D., Nichols, C. D., & Foster, T. P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.859866 · Cited by 3
Sensitive and high-throughput bioanalysis of fluoxetine and nor-fluoxetine in rabbit and human plasma using SPE-LC-MS/MS
Prasad, Y. D., Chhonker, Y. S., Chandasana, H., Laxman, T. S., Bala, V., Kanojiya, S., Ghatak, S., & Bhatta, R. S. (2015) · Analytical Methods · doi:10.1039/c5ay00891c · Cited by 3
Inverse Virtual Screening in Drug Repositioning: Detailed Investigation and Case Studies
Warrier, S. B., & Kharkar, P. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-31759-5_5 · Cited by 3
Construction of a subgenomic CV-B3 replicon expressing emerald green fluorescent protein to assess viral replication of a cardiotropic enterovirus strain in cultured human cells
Wehbe, M., Huguenin, A., Lévêque, N., Semler, B. L., Hamzé, M., Andréoletti, L., & Bouin, A. (2016) · Journal of Virological Methods · doi:10.1016/j.jviromet.2016.01.005 · Cited by 3
Construction and In Vitro and In Vivo Analysis of Coxsackievirus B4 Reporter Viruses: Attenuated Virulence but Highly Efficient for Antiviral Drug Screening and Evaluation
Liu, Q., Wang, H., Xuan, X., Liu, H., Tang, B., Zhou, Z., Zhang, L., Qiu, S., Li, X., Tian, X., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70433 · Cited by 2
Bioinformatic Approaches for Repurposing and Repositioning Antibiotics, Antiprotozoals, and Antivirals
Xia, X. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00023-7 · Cited by 1
Protective effects of psychiatric medications against COVID-19 mortality before vaccines
Machado‐Vieira, R., Krause, T. M., Jones, G. H., Teixeira, A. L., Shahani, L., Lane, S. D., Soares, J. C., & Truong, C. (2025) · PLoS ONE · doi:10.1371/journal.pone.0310438 · Cited by 1
Advances in Antiviral Drug Development Targeting Enteroviruses: From Viral Proteins to Host Factors
Lu, J., Li, C., Cui, W., Du, Y., Geng, J., & Zhang, W. (2026) · Viruses · doi:10.3390/v18040476 · Cited by 1
Targeting Picornavirus Nonstructural 2C Protein: Structure, Function, and Antiviral Discovery
Li, K., Fan, G., Zhang, W., & Wang, J. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6c00387 · Cited by 1
Onaylanmış Merkezi Etkili İlaçların Antiviral Aktivitesi: Bir Anlatı İncelemesi
Elhadi, E., Abdulaziz, L., Abdallah, E. A., ALNOOR, F. A. E. A., & Yousef, B. A. (2022) · Hacettepe University Journal of the Faculty of Pharmacy · doi:10.52794/hujpharm.1047842 · Cited by 1
Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day
Eugene, A. R. (2022) · F1000Research · doi:10.12688/f1000research.53275.3 · Cited by 2
Evaluating the Potential of Repurposing Commercially Available Drugs for the Treatment of Viral Infections
McEwan, B. C. (2021) · Digital Commons - USU (Utah State University) · doi:10.26076/6f41-58d6
From repurposed drugs to pan-enterovirus and rhinovirus inhibitors
Bauer, L. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/216
iPSCs for modeling coxsackievirus infection
Belkaya, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823808-0.00004-3
Pharmacology of novel approaches designed to target picornaviral infections
Hasan, O. (2021) · Open Access at Essex (University of Essex)
Antidepressants with antimicrobial activity? A promising therapeutic strategy
González, G. M., Montoya, A. M., Andrade-Torres, A., Becerril-García, M. A., & Treviño‐Rangel, R. D. J. (2022) · Medicina Universitaria · doi:10.24875/rmu.22000036
Current therapeutic strategies and novel antiviral compounds for the treatment of nonpolio enteroviruses
Suresh, A. J., & Dass, R. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91814-5.00015-5
2C protein of Enterovirus: key protein of viral replication and antiviral target
Kazzi, P. E., Yaacoub, C., Fajloun, Z., Vanelle, P., Decroly, É., Coutard, B., & Barral, K. (2023) · Virologie · doi:10.1684/vir.2023.1001
Chapter 12. Fluoxetine and Fluvoxamine
Aboujaoude, E. N., Rosenbaum, J. F., Ionescu, D. F., & Koran, L. M. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as12
The potential of leritrelvir repositioning for the treatment of coxsackievirus B4 and common enterovirus infections
Liu, Q., Tang, B., Xuan, X., Wang, H., Liu, H., Zhang, L., Qiu, S., You, A., Mo, C., Li, X., et al. (2026) · Antiviral Research · doi:10.1016/j.antiviral.2026.106367
Etude des caractères génétiques des Entérovirus persistants dans les tissus cardiaques de sujets atteints de cardiomyopathie dilatée idiopathique
Bouin, A. (2015) · theses.fr (ABES) · doi:10.70675/92a12c45z71a9z42b7zb1a6z36f26bf6bf8b
Etude de l’activité de réplication des formes de Coxsackievirus B3 complètes et tronquées dans la région 5’non codante dans un modèle de cardiomyocytes humains primaires en culture.
Wehbe, M. (2016) · theses.fr (ABES) · doi:10.70675/1db0c342z1e9bz402dz94e5z5315ecd9c739
Identification d’échanges génétiques modulaires entre des populations d’ARN complets ou tronqués en région 5’non codante d’Entérovirus du groupe B dans des cardiomyocytes humains primaires : impact sur la pathogénèse des cardiomyopathies dilatées inexpliquées chez l’Homme
Gretteau, P.-A. (2018) · theses.fr (ABES) · doi:10.70675/f4be6f18z80a8z47fcza5bfz0d10a6f6473c
Détection moléculaire des formes complètes et tronquées en région 5’non codante des Entérovirus et conséquences sur la réponse inflammatoire chez des patients souffrant de myocardite ou de cardiomyopathie dilatée
N’Guyen, Y. (2019) · theses.fr (ABES) · doi:10.70675/cfed4bb1z1fd6z47e3z9a31zce9bf6bc90ad

Authors: Zuo, J., Quinn, K. K., Kye, S., Cooper, P., Damoiseaux, R., & Krogstad, P.
Affiliations: University of California, Los Angeles (US)
California NanoSystems Institute (US)
ORCID: Damoiseaux, Robert
Krogstad, Paul
Venue: Antimicrobial Agents and Chemotherapy
Publisher: American Society for Microbiology
Published: 2012-09
Volume: 56
Issue: 9
Pages: 4838-4844
ISSN: 0066-4804 (ISSN-L)
1098-6596
DOI: 10.1128/aac.00983-12
PMC: PMC3421851
OpenAlex: W2131952231
Cited by: 104
References: 49
Citations by year: 2026: 8 · 2025: 4 · 2024: 4 · 2023: 5 · 2022: 17 · 2021: 14 · 2020: 12 · 2019: 10 · 2018: 6 · 2017: 1 · 2016: 8 · 2015: 8 · 2014: 5 · 2013: 2
FWCI: 3.09
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Antimicrobial Agents and Chemotherapy (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: U.S. Food and Drug Administration
Topics: Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Mosquito-borne diseases and control
Keywords: fluoxetine, Coxsackie virus, enterovirus infection, antiviral agents, viral RNA synthesis, norfluoxetine, selective serotonin reuptake inhibitors, small molecule screening, viral replication inhibition
MeSH terms: Antidepressive Agents, Antiviral Agents, Enterovirus, Fluoxetine, HeLa Cells, Humans, RNA, Viral, Transfection, Virus Replication, Genes, Reporter, Inhibitory Concentration 50, Green Fluorescent Proteins, Small Molecule Libraries, High-Throughput Screening Assays

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Fluoxetine Is a Potent Inhibitor of Coxsackievirus Replication

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks